Abstract
Purpose
Iodine-131-m-iodobenzylguanidine ([131I]mIBG)-targeted radionuclide therapy (TRT) is a standard treatment for recurrent or refractory neuroblastoma with response rates of 30–40 %. The aim of this study is to demonstrate patient-specific dosimetry using quantitative [124I]mIBG positron emission tomography/X-ray computed tomography (PET/CT) imaging with a GEometry ANd Tracking 4 (Geant4)-based Monte Carlo method for better treatment planning.
Procedures
A Monte Carlo dosimetry method was developed using the Geant4 toolkit with voxelized anatomical geometry and source distribution as input. The presegmented hybrid computational human phantoms developed by the University of Florida and the National Cancer Institute (UF/NCI) were used as a surrogate to characterize the anatomy of a given patient. S values for I-131 were estimated by the phantoms coupled with Geant4 and compared with those estimated by OLINDA|EXM and MCNPX for the newborn model. To obtain patient-specific biodistribution of [131I]mIBG, a 10-year-old girl with relapsed neuroblastoma was imaged with [124I]mIBG PET/CT at four time points prior to the planned [131I]mIBG TRT. The organ- and tumor-absorbed doses of the clinical case were estimated with the Geant4 method using the modified UF/NCI 10-year-old phantom with tumors and the patient-specific residence time.
Results
For the newborn model, the Geant4 S values were consistent with the MCNPX S values. The S value ratio of the Geant4 method to OLINDA|EXM ranged from 0.08 to 6.5 of all major organs. The [131I]mIBG residence time quantified from the pretherapy [124I]mIBG PET/CT imaging of the 10-year-old patient was mostly comparable to those previously reported. Organ-absorbed dose for the salivary glands was 98.0 Gy, heart wall 36.5 Gy, and liver 34.3 Gy, while tumor-absorbed dose ranged from 143.9 to 1,641.3 Gy in different sites.
Conclusions
Patient-specific dosimetry for [131I]mIBG TRT was accomplished using pretherapy [124I]mIBG PET/CT imaging and a Geant4-based Monte Carlo dosimetry method. The Geant4 method with quantitative pretherapy imaging can provide dose estimates to normal organs and tumors with more realistic simulation geometry, and thus may improve treatment planning for [131I]mIBG TRT.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Matthay KK, Tan JC, Villablanca JG et al (2006) Phase I dose escalation of iodine-131-metaiodobenzylguanidine with myeloablative chemotherapy and autologous stem-cell transplantation in refractory neuroblastoma: a new approaches to Neuroblastoma Therapy Consortium Study. J Clin Oncol 24:500–6
Matthay KK, Weiss B, Villablanca JG et al (2012) Dose escalation study of no-carrier-added 131I-metaiodobenzylguanidine for relapsed or refractory neuroblastoma: new approaches to neuroblastoma therapy consortium trial. J Nucl Med 53:1155–63
Matthay KK, Yanik G, Messina J et al (2007) Phase II study on the effect of disease sites, age, and prior therapy on response to iodine-131-metaiodobenzylguanidine therapy in refractory neuroblastoma. J Clin Oncol 25:1054–60
Carlin S, Mairs RJ, McCluskey AG et al (2003) Development of a real-time polymerase chain reaction assay for prediction of the uptake of meta-[(131)I]iodobenzylguanidine by neuroblastoma tumors. Clin Cancer Res 9:3338–44
Treuner J, Feine U, Niethammer D et al (1984) Scintigraphic imaging of neuroblastoma with [131-I]iodobenzylguanidine. Lancet 1:333–4
Matthay KK, DeSantes K, Hasegawa B et al (1998) Phase I dose escalation of 131I-metaiodobenzylguanidine with autologous bone marrow support in refractory neuroblastoma. J Clin Oncol 16:229–36
DuBois SG, Matthay KK (2013) 131I-Metaiodobenzylguanidine therapy in children with advanced neuroblastoma. Q J Nucl Med Mol Im 57:53–65
Wilson JS, Gains JE, Moroz V, et al. (2013) A systematic review of I-meta iodobenzylguanidine molecular radiotherapy for neuroblastoma. Eur J Cancer
Yoriyaz H, Stabin MG, dos Santos A (2001) Monte Carlo MCNP-4B-based absorbed dose distribution estimates for patient-specific dosimetry. J Nucl Med 42:662–9
Stabin MG, Yoriyaz H (2002) Photon specific absorbed fractions calculated in the trunk of an adult male voxel-based phantom. Health Phys 82:21–44
Lee C, Park S, Lee JK (2007) Specific absorbed fraction for Korean adult voxel phantom from internal photon source. Radiat Prot Dosimet 123:360–8
Lamart S, Bouville A, Simon SL et al (2011) Comparison of internal dosimetry factors for three classes of adult computational phantoms with emphasis on I-131 in the thyroid. Phys Med Biol 56:7317–35
Cristy M, Eckerman KF (1987) Specific absorbed fractions of energy at various ages from internal photon sources: 1, methods. Oak Ridge National Laboratory, Oak Ridge
Lee C-L, Wahnishe H, Sayre GA et al (2010) Radiation dose estimation using preclinical imaging with 124I-metaiodobenzylguanidine (MIBG) PET. Med Phys 37:4861
Seo Y, Gustafson WC, Dannoon SF et al (2012) Tumor dosimetry using [124I]m-iodobenzylguanidine microPET/CT for [131I]m-iodobenzylguanidine treatment of neuroblastoma in a murine xenograft model. Mol Imag Biol 14:735–42
Moroz MA, Serganova I, Zanzonico P et al (2007) Imaging hNET reporter gene expression with 124I-MIBG. J Nucl Med 48:827–36
Agostinelli S, Allison J, Amako K et al (2003) Geant4—a simulation toolkit. Nucl Instrum Methods Phys Res A 506:250–303
Allison J, Amako K, Apostolakis J et al (2006) Geant4 developments and applications. IEEE Trans Nucl Sci 53:270–278
Stabin MG, Sparks RB, Crowe E (2005) OLINDA/EXM: the second-generation personal computer software for internal dose assessment in nuclear medicine. J Nucl Med 46:1023–7
Wayson M, Lee C, Sgouros G et al (2012) Internal photon and electron dosimetry of the newborn patient—a hybrid computational phantom study. Phys Med Biol 57:1433–57
Lee C, Lodwick D, Hasenauer D, Williams JL, Bolch WE (2007) Hybrid computational phantoms of the male and female newborn patient: NURBS-based whole-body models. Phys Med Biol 52:3309–33
Lee C, Lodwick D, Hurtado J et al (2010) The UF family of reference hybrid phantoms for computational radiation dosimetry. Phys Med Biol 55:339–63
Loevinger R, Budinger TF, Watson EE (1988) MIRD primer for absorbed dose calculations. Society of Nuclear Medicine New York
Johnson PB, Bahadori AA, Eckerman KF, Lee C, Bolch WE (2011) Response functions for computing absorbed dose to skeletal tissues from photon irradiation—an update. Phys Med Biol 56:2347–65
Pafundi D, Lee C, Watchman C et al (2009) An image-based skeletal tissue model for the ICRP reference newborn. Phys Med Biol 54:4497–531
Pafundi D, Rajon D, Jokisch D, Lee C, Bolch W (2010) An image-based skeletal dosimetry model for the ICRP reference newborn—internal electron sources. Phys Med Biol 55:1785–814
Xie T, Bolch WE, Lee C, Zaidi H (2013) Pediatric radiation dosimetry for positron-emitting radionuclides using anthropomorphic phantoms. Med Phys 40:102502
Tuli J (2014) Evaluated Nuclear Structure Data File (ENSDF) Retrieval. http://www.nndc.bnl.gov/ensdf/
Hauf S, Kuster M, Batic M, et al. (2013) Radioactive decays in Geant4
Loening AM, Gambhir SS (2003) AMIDE: a free software tool for multimodality medical image analysis. Mol Imaging 2:131–137
Bazan JG, Koong AC, Kapp DS et al (2013) Metabolic tumor volume predicts disease progression and survival in patients with squamous cell carcinoma of the anal canal. J Nucl Med 54:27–32
Ciernik IF, Dizendorf E, Baumert BG et al (2003) Radiation treatment planning with an integrated positron emission and computer tomography (PET/CT): a feasibility study. Int J Radiat Oncol Biol Phys 57:853–863
Evans JF, Stabin MG, Stubbs JB (1995) Specific absorbed fractions of energy from internal photon sources in brain tumor and cerebrospinal fluid. Med Phys 22:331–40
Stabin MG, Siegel JA (2003) Physical models and dose factors for use in internal dose assessment. Health Phys 85:294–310
Johnson PB, Whalen SR, Wayson M et al (2009) Hybrid patient-dependent phantoms covering statistical distributions of body morphometry in the US adult and pediatric population. Proc IEEE 97:2060–2075
Matthay KK, Panina C, Huberty J et al (2001) Correlation of tumor and whole-body dosimetry with tumor response and toxicity in refractory neuroblastoma treated with 131I-MIBG. J Nucl Med 42:1713–21
Acknowledgments
The authors would like to thank the clinical coordinators, technologists, nurses, and physicians who made this study possible at UCSF. We also would like to thank Jungwook Shin, Ph.D., for helpful advice for developing Geant4 simulations. This work was supported in part by the National Cancer Institute under grant R01 CA154561 and PO181403 and by the Alex Scott Lemonade and Dougherty Foundations.
Conflict of Interest
The authors declare that they have no conflict of interest.
Author information
Authors and Affiliations
Corresponding author
Electronic supplementary material
Below is the link to the electronic supplementary material.
ESM 1
(PDF 524 kb)
Rights and permissions
About this article
Cite this article
Huang, Sy., Bolch, W.E., Lee, C. et al. Patient-Specific Dosimetry Using Pretherapy [124I]m-iodobenzylguanidine ([124I]mIBG) Dynamic PET/CT Imaging Before [131I]mIBG Targeted Radionuclide Therapy for Neuroblastoma. Mol Imaging Biol 17, 284–294 (2015). https://doi.org/10.1007/s11307-014-0783-7
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11307-014-0783-7